07 Jan 2001

MAXALT® 5 (MAXALT® 5 mg/-10 mg Tabletten) - Deutschland

Updated: 07 Jan 2001

MAXALT® 5 mg | -10 mg; lingua 5 mg | -10 mg

Akute Behandl. der Kopfschmerzphase von Migräneanfällen mit od. ohne Aura.

MAXALT® 5 Description, Presentation and Dosage

MAXALT® 5 Description

MAXALT® 5 Drug Class Description

Einzelstoffe

MAXALT® 5 Drug Description

1 Tbl. enth.: Rizatriptanbenzoat 7,265 mg/14,53 mg (entspr. 5 mg/10 mg Rizatriptan).

MAXALT® 5 Generic Name

MAXALT® 5 mg/-10 mg Tabletten

MAXALT® 5 Presentation

MAXALT® 5 Presentation

MAXALT® 5 mg/-10 mg; lingua 5 mg/-10 mg

MAXALT® 5 Manufacturer

MSD

Related Learning Zones

CLL Knowledge Centre and CME

CLL Knowledge Centre and CME

The Chronic Lymphocytic Leukaemia (CLL) Knowledge Centre contains useful information arranged within four main sections: ‘Disease Awareness’, ‘Events’, ‘Resources’, and 'CME'. Healthcare professionals will find information on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment and management options, an upcoming events calendar and an external links listing,

The CME activity ‘Treatment Optimisation in Chronic Lymphocytic Leukaemia’ has been EACCME-accredited and awarded 1 CME credit. Test your knowledge by answering quiz questions based on patient case study scenarios.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

Cystic fibrosis (CF) is a genetic condition caused by a defect in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. The Cystic Fibrosis Knowledge Centre provides healthcare professionals with access to disease awareness information, emerging and established treatment options and current best practice based on recently updated guidelines by the European Cystic Fibrosis Society (ECFS). A resources section contains external links to upcoming medical conferences and patient support groups.

This resource is developed by EPG Health Media for epgonline.org, supported by an independent educational grant from Vertex.

MAXALT® 5 Dosage

MAXALT® 5 Adult Dosage

Lactose 1H2O, mikrokristalline Cellulose, Maisquellstärke, Eisen(III)-oxid, rot (E 172), Magnesiumstearat.

MAXALT® 5 Child Dosage


MAXALT® lingua 5 mg/-10 mg Schmelztabletten
Zus.: 1 Schmelztbl. enth.: Rizatriptanbenzoat 7,265 mg/14,53 mg (entspr. 5 mg/10 mg Rizatriptan).
Weit. Bestandteile: Gelatine, D-Mannitol, Glycin, Aspartam, Pfefferminzaroma.

MAXALT® 5 Precautions, Reactions and Contraindications

MAXALT® 5 Special Precautions

MAXALT® 5 Special Precautions

Schwere Leberfunktionseinschränkung, schwere Niereninsuffizienz, Pat. mit einem zerebrovaskulären Ereignis/TIA in der Krankheitsgeschichte, mäßige od. schwere Hypertonie od. unbehandelte leichte Hypertonie, ischämische Herzkrankheit (Angina pectoris, Herzinfarkt in der Vorgeschichte, dokumentierte stumme Ischämie), Anzeichen od. Symptome einer ischämischen Herzerkrankung, Prinzmetal Angina, periphere Gefäßerkrankung, gleichz. Verabreichung von Ergotamin, Ergotaminderivaten (einschließl. Methysergid) od. anderen 5-HT1B/1D-Rezeptoragonisten, gleichz. Verabreichung von MAO-Hemmern od. Einsatz innerhalb von 2 Wo. nach Absetzen einer MAO-Hemmer-Therapie.

Related Drugs - Neurological Disorders

Back to top